Article thumbnail

The Impact of Matching Vaccine Strains and Post-SARS Public Health Efforts on Reducing Influenza-Associated Mortality among the Elderly

By Ta-Chien Chan, Chuhsing Kate Hsiao, Chang-Chun Lee, Po-Huang Chiang, Chuan-Liang Kao, Chung-Ming Liu and Chwan-Chuen King

Abstract

Public health administrators do not have effective models to predict excess influenza-associated mortality and monitor viral changes associated with it. This study evaluated the effect of matching/mismatching vaccine strains, type/subtype pattern changes in Taiwan's influenza viruses, and the impact of post-SARS (severe acute respiratory syndrome) public health efforts on excess influenza-associated mortalities among the elderly. A negative binomial model was developed to estimate Taiwan's monthly influenza-associated mortality among the elderly. We calculated three winter and annual excess influenza-associated mortalities [pneumonia and influenza (P&I), respiratory and circulatory, and all-cause] from the 1999–2000 through the 2006–2007 influenza seasons. Obtaining influenza virus sequences from the months/years in which death from P&I was excessive, we investigated molecular variation in vaccine-mismatched influenza viruses by comparing hemagglutinin 1 (HA1) of the circulating and vaccine strains. We found that the higher the isolation rate of A (H3N2) and vaccine-mismatched influenza viruses, the greater the monthly P&I mortality. However, this significant positive association became negative for higher matching of A (H3N2) and public health efforts with post-SARS effect. Mean excess P&I mortality for winters was significantly higher before 2003 than after that year [mean ± S.D.: 1.44±1.35 vs. 0.35±1.13, p = 0.04]. Further analysis revealed that vaccine-matched circulating influenza A viruses were significantly associated with lower excess P&I mortality during post-SARS winters (i.e., 2005–2007) than during pre-SARS winters [0.03±0.06 vs. 1.57±1.27, p = 0.01]. Stratification of these vaccine-matching and post-SARS effect showed substantial trends toward lower elderly excess P&I mortalities in winters with either mismatching vaccines during the post-SARS period or matching vaccines during the pre-SARS period. Importantly, all three excess mortalities were at their highest in May, 2003, when inter-hospital nosocomial infections were peaking. Furthermore, vaccine-mismatched H3N2 viruses circulating in the years with high excess P&I mortality exhibited both a lower amino acid identity percentage of HA1 between vaccine and circulating strains and a higher numbers of variations at epitope B. Our model can help future decision makers to estimate excess P&I mortality effectively, select and test virus strains for antigenic variation, and evaluate public health strategy effectiveness

Topics: Research Article
Publisher: Public Library of Science
OAI identifier: oai:pubmedcentral.nih.gov:2892467
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2006). Antibody response to influenza vaccination in the elderly: a quantitative review.
  2. (2008). Cabinet expands mini links with mainland. Taiwan Today.
  3. (2009). Comment on Ndifon et al., ‘‘On the use of hemagglutination-inhibition for influenza surveillance: Surveillance data are predictive of influenza vaccine effectiveness’’.
  4. (2008). Complications of viral influenza.
  5. (2008). Establishing a nationwide emergency department-based syndromic surveillance system for better public health responses in Taiwan.
  6. (2007). Exploration of the emergence of the Victoria lineage of influenza B virus.
  7. (2004). Factors influencing the wearing of facemasks to prevent the severe acute respiratory syndrome among adult Chinese in Hong Kong.
  8. (2009). flu pandemic by country.
  9. (2008). Global trends in emerging infectious diseases.
  10. (2005). Handwashing practice and the use of personal protective equipment among medical students after the SARS epidemic in Hong Kong.
  11. (2007). Impact of influenza vaccination on major cause-specific mortality.
  12. (2005). Impact of influenza vaccination on seasonal mortality in the US elderly population.
  13. (2007). Impact of SARS on healthcare utilization by disease categories: implications for delivery of healthcare services.
  14. (2006). Increasing appearance of reassortant influenza B virus in Taiwan from
  15. (2009). Influenza A viruses with truncated NS1 as modified live virus vaccines: pilot studies of safety and efficacy in horses.
  16. (2008). Influenza B virus NS1-truncated mutants: live-attenuated vaccine approach.
  17. (2010). Influenza Express in Taiwan - week 8,
  18. (2005). Influenza in Taiwan: seasonality and vaccine strain match.
  19. (2008). Influenza vaccine strain selection and recent studies on the global migration of seasonal influenza viruses.
  20. (2009). Influenza virus antigenic variation, host antibody production and new approach to control epidemics.
  21. (2009). Influenza virus CTL epitopes, remarkably conserved and remarkably variable.
  22. (2006). Influenzarelated mortality in the Italian elderly: no decline associated with increasing vaccination coverage.
  23. (2005). Laboratorybased surveillance and molecular epidemiology of influenza virus in Taiwan.
  24. (2009). Live attenuated influenza viruses containing NS1 truncations as vaccine candidates against H5N1 highly pathogenic avian influenza.
  25. (2004). Mapping the antigenic and genetic evolution of influenza virus.
  26. (2003). Mortality associated with influenza and respiratory syncytial virus in the United States.
  27. (2009). Mortality from pandemic A/H1N1 2009 influenza in England: public health surveillance study.
  28. (2007). Nonpharmaceutical interventions implemented by US cities during the 1918– 1919 influenza pandemic.
  29. (2009). On the use of hemagglutinationinhibition for influenza surveillance: surveillance data are predictive of influenza vaccine effectiveness.
  30. Organization. WHO Recommendations for Influenza Vaccine Composition.
  31. (2008). Process of standardized antiserum and antigen of human influenza viruses in Taiwan.
  32. (1998). Seasonal trends of viral respiratory tract infections in the tropics.
  33. (2004). Severe acute respiratory syndrome epidemic and change of people’s health behavior in China.
  34. (2007). Simultaneous amino acid substitutions at antigenic sites drive influenza A hemagglutinin evolution.
  35. (2002). Statistical inference. Australia: Duxbury/Thomson Learning.
  36. (2009). T-cell tolerance for variability in an HLA class I-presented influenza A virus epitope.
  37. (2009). Taipei’s use of a multi-channel mass risk communication program to rapidly reverse an epidemic of highly communicable disease.
  38. (2006). The
  39. (2008). The global circulation of seasonal influenza A (H3N2) viruses.
  40. (2008). The impact of SARS on hospital performance.
  41. (2008). The reform of the hospital accreditation system in Taiwan.
  42. (2008). Vaccination and antigenic drift in influenza.
  43. (2007). Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev.
  44. (2006). Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev 3:
  45. (2009). Widespread public misconception in the early phase of the H1N1 influenza epidemic.